Skip to main content

GE Healthcare and Dharmacon, Benitec, NCI and NIH, and New York Academy of Sciences

Premium

GE Healthcare to Market Dharmacon RNAi Products in Japan

Dharmacon said this week that it has signed a deal making GE Healthcare the exclusive distribution agent for its RNAi research products in Japan.

Specific terms of the arrangement were not disclosed.


Benitec Names Cancer as Third Disease Area

Benitec reported in its annual general meeting presentation last week that cancer is the third disease area on which the company will focus its drug-development efforts.

The company is also pursuing treatments for HIV and hepatitis C.

Benitec noted in the presentation that it is negotiating with possible development and commercialization partners for the cancer program, which is expected to enter clinical trials in the third quarter of 2005.


NCI to Host NIH Symposium on Therapeutic Oligos

The National Cancer Institute’s Center for Cancer Research is sponsoring the upcoming National Institutes of Health Symposium on Therapeutic Oligonucleotides: Transcriptional and Translational Strategies for Silencing Gene Expression.

The event is scheduled for Dec. 13 and 14, and will be held in Bethesda, Md., at the NIH’s Masur Auditorium.

According to the NCI, the conference is focused on such areas as antisense, RNAi, triple-helix, gene repair, DNA chips, and CpG immune modulatory oligonucleotides, as the development of these agents to clinical medicines and as basic research tools.

Specific talks include ones on designing better siRNAs; splice switching oligonucleotides; delective delivery of oligonucleotides and medicinal drugs by receptor-mediated endocytosis; development of a function overriding siRNA silencing in mammalian cells; transcription factor decoys; and modified oligonucleotide hybridization and genetic insertion.

Speakers slated to present at the event include Dharmacon’s Anastasia Khvorova; Barry Polisky of Sirna Therapeutics; Frank Szoka of the University of California, San Francisco; the City of Hope’s John Rossi; and Serge Beaucage from the US Food and Drug Administration.

Details on the symposium, including registration information, can be found at https://cms.palladianpartners.com/cms/1098206928/.


NYAS Schedules RNAi Meeting for December

The New York Academy of Sciences has scheduled its latest RNAi Discussion Group meeting for Dec. 14.

The event, entitled “Structural and Mechanistic Insights into RNAi Components and Machinery,” will be held at the NYAS.

The meeting will feature speakers Dinshaw Patel from Memorial Sloan-Kettering Cancer Center; Xinhua Ji from the National Institutes of Health; and Phillip Zamore from the University of Massachusetts Medical School.

Details about the discussion group can be found at http://www.nyas.org/channels/index.asp?channelID=11.

The Scan

Not Kept "Clean and Sanitary"

A Food and Drug Administration inspection uncovered problems with cross contamination at an Emergent BioSolutions facility, the Wall Street Journal reports.

Resumption Recommendation Expected

The Washington Post reports that US officials are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine.

Canada's New Budget on Science

Science writes that Canada's new budget includes funding for the life sciences, but not as much as hoped for investigator-driven research.

Nature Papers Examine Single-Cell, Multi-Omic SARS-CoV-2 Response; Flatfish Sequences; More

In Nature this week: single-cell, multi-omics analysis provides insight into COVID-19 pathogenesis, evolution of flatfish, and more.